RGLS Showing Interesting Levels

NASDAQ:RGLS   Regulus Therapeutics Inc.
RGLS continues pivoting around that 618 Fib line. Overall, it has held a clear uptrend despite the pullback. Trend line lines up almost perfectly with the latest higher lows put in. RNA companies remain a focus. In this case, it's not covid but kidney diseases.

"In mid-May, Regulus Therapeutics announced an incremental update of its autosomal dominant polycystic kidney disease program. The CEO of the company, Jay Hagan said, “As previously reported, the ninth and final patient was trending well at the end of the dosing period and saw their polycystin levels continue to rise until study completion, twenty-eight days after the last dose. This pattern was generally consistent across the first cohort and further enhanced the overall mean changes from baseline for both biomarkers."

PLUS upcoming presentation of RGLS4326 for the treatment of ADPKD at the PKD Connect Conference 2021 this Friday (6/25) could be something to keep in mind right now too.

Quote Source: 7 Hot Penny Stocks to Watch That Are Trending Right Now


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.